Johnson & Johnson Advances Cardiology Crohn’s Care And Robotics As Shares Lag

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge.

Johnson & Johnson (NYSE:JNJ) has launched the Shockwave C2 Aero Coronary IVL Catheter for calcified coronary artery disease, adding to its intravascular lithotripsy portfolio.

The company reported key clinical results for TREMFYA in perianal fistulizing Crohn’s disease, the first major trial in this setting in roughly 20 years.

JNJ-4804 produced positive data in highly refractory inflammatory bowel disease patients, pointing to potential options in difficult to treat cases.

The OTTAVA Robotic Surgical System completed a successful first in human study, marking progress in Johnson & Johnson’s MedTech franchise.

For investors watching NYSE:JNJ, these updates sit at the intersection of pharmaceuticals and medical devices, two core lines of business for the company. The focus on coronary disease, Crohn’s disease and robotic surgery aligns with large, procedure heavy areas of healthcare that regularly attract attention from hospitals, clinicians and payers.

Readers may want to track how these products and clinical programs move through regulatory review, adoption by clinicians and potential competitive responses. The timing of further data releases, approvals or commercial launches could be useful signposts for assessing how meaningful these developments become within Johnson & Johnson’s broader portfolio.

Stay updated on the most important news stories for Johnson & Johnson by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Johnson & Johnson.

📰 Beyond the headline: 2 risks and 3 things going right for Johnson & Johnson that every investor should see.

⚖️ Price vs Analyst Target: At US$224.26, Johnson & Johnson trades about 11% below the US$252.42 analyst consensus target.

✅ Simply Wall St Valuation: Simply Wall St currently estimates the stock is trading about 40% below its assessed fair value.

❌ Recent Momentum: The share price is down 6.0% over the last 30 days.

There is only one way to know the right time to buy, sell or hold Johnson & Johnson. Head to Simply Wall St's company report for the latest analysis of Johnson & Johnson's Fair Value.

📊 The new coronary IVL catheter, Crohn’s disease data and OTTAVA robotic progress all extend Johnson & Johnson's reach across cardiology, immunology and MedTech.

📊 Watch how quickly these assets move through regulatory milestones, adoption in hospitals and any revenue contribution discussed on future earnings calls.

⚠️ With two flagged minor risks, including significant insider selling over the past 3 months and a high level of debt, balance the product news against the capital structure and insider signals.

For the full picture including more risks and rewards, check out the complete Johnson & Johnson analysis. Alternatively, you can check out the community page for Johnson & Johnson to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include JNJ.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com